ACE2 and COVID-19: Can insight into the disease mechanisms for SARS-CoV-2 obtained in cells and preclinical studies be translated into the critically ill COVID-19 patients employing e.g. infusion of soluble recombinant ACE2, Ang1–7, AT2 receptor and/or Mas receptor agonists and nitric oxide?